1. In Vivo
  2. >>Leadership
  3. >>C-Suite Speaks

Inside Recursion’s Pipeline: Najat Khan On AI, Data Science And Biotech Innovation

 
• By David Wild

In Vivo caught up with Najat Khan, chief R&D and commercial officer at Recursion since mid-2024, about her new roles, the special combination with Exscientia and the company's clinical pipeline.

Najat Khan
Najat Khan is Recursion’s new chief R&D and chief commercial officer. • Source: Recursion

Najat Khan has built her career at the intersection of drug development and technological innovation. As chief R&D and commercial officer at Recursion, she is helping to scale one of biotech’s (or techbio’s) most ambitious efforts to industrialize drug discovery through artificial intelligence (AI).

Before joining Recursion in 2024, Khan spent over six years at Johnson & Johnson, where she served as chief data...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from C-Suite Speaks

More from Market Intelligence

Late-Stage GLP-1 Drug Trials Outside The Cardiometabolic Space

 
• By David Wild

A look at Novo Nordisk, Eli Lilly and other companies' late-stage clinical studies of GLP-1 drugs in indications ranging from neurodegeneration to oncology, and alcoholic liver disease to autoimmune conditions.

UK Bets On Regulatory Innovation As Competitive Advantage In Synthetic Biology

 
• By David Wild

The UK government has prioritized synthetic biology and created a "concierge service" for biotechs just as the US cuts science funding.

The 360 Degrees Of European Biotech Financing In 2025

 
• By Jo Shorthouse

Almost halfway through 2025, and financing for European biotech could be described as challenging. Market volatility, geopolitical instability and trade barriers all loom large in biotech CEO minds when pitching for funding. In Vivo talked to biotechs and investors to gain a realistic view of the current market for company funding so far this year.